Your Health, We Care
Release date: 2026-02-05 17:00:40 Recommended: 101
Cabozantinib is a non-chemotherapy prescription medication classified as a tyrosine kinase inhibitor (TKI). It is administered as a tablet, taken once daily, or as directed by a healthcare provider.
Cabozantinib is a prescription medicine used to treat the following conditions:
Cabozantinib may be used:
In combination with nivolumab to treat adult patients with advanced (metastatic) renal cell carcinoma who have not received prior treatment for advanced disease;
As a single agent to treat adult patients with advanced renal cell carcinoma.
For adult patients with hepatocellular carcinoma who have received prior treatment with sorafenib.
Approved for adult and pediatric patients 12 years of age and older who meet all of the following criteria:
Have differentiated thyroid cancer that has spread (locally advanced or metastatic);
Have experienced disease progression after treatment with an anti-vascular endothelial growth factor receptor (VEGFR) targeted therapy;
Are no longer eligible for, or are unable to receive, radioactive iodine treatment.
Approved for adult and pediatric patients 12 years of age and older who meet all of the following criteria:
Have pancreatic neuroendocrine tumors (pNET) or extra-pancreatic neuroendocrine tumors (epNET);
Have received prior treatment;
Are ineligible for surgical resection;
Have tumors that have spread (locally advanced or metastatic).
The safety and efficacy of cabozantinib have not been established in children younger than 12 years of age.
Before deciding to use this medicine, you must weigh the risks and benefits, a decision to be made jointly by you and your doctor. Consider the following before using cabozantinib:
Tell your doctor if you have had an unusual or allergic reaction to this medicine or any other medications. Inform your healthcare provider if you have any other type of allergy (e.g., to foods, dyes, preservatives, animals, etc.). Read the labels and ingredient lists carefully for over-the-counter (OTC) medications.
No age- and efficacy-related studies have been conducted for cabozantinib in children younger than 12 years for the treatment of differentiated thyroid cancer or pancreatic cancer. No clinical studies have been performed for the use of cabozantinib in children to treat medullary thyroid cancer, liver cancer, or advanced kidney cancer. Its safety and efficacy have not been confirmed in this population.
To date, clinical studies of cabozantinib tablets have not identified any geriatric-specific issues that limit its use in elderly patients.
No age- and efficacy-related studies have been conducted for cabozantinib capsules in the geriatric population; however, there are no reported geriatric-specific adverse reactions.
There are insufficient studies to evaluate the risk to infants from the use of cabozantinib in lactating women. The potential benefits and risks to the infant must be weighed before using this medicine during lactation.
